[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Yarrow Bioscience, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100646925","phase-2-evaluation-of-yb-101-for-safety-tolerability-pharmacokinetics-and-efficacy-in-graves-disease-100646925",false,"NCT07682896","Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease","A Randomized, Blinded, Placebo-Controlled, Two-Part, Phase 2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of YB-101 in Participants With Graves' Disease","Inclusion Criteria:\n\n* Have a documented diagnosis of Graves' Disease confirmed by the presence of thyroid-stimulating hormone receptor antibodies (TRAbs) by medical history or screening laboratory assessment\n* Have a pre-existing diagnosis of TED or, conversely, no evidence of TED at the ophthalmological examination performed during screening\n* Additional inclusion criteria are defined in the protocol\n\nExclusion Criteria:\n\n* Previously treated with radioactive iodine (RAI) therapy or underwent total thyroidectomy\n* Received any dose of levothyroxine, desiccated thyroid extract, or T3 within 6 weeks before screening\n* Current treatment with teprotumumab or exposure to teprotumumab within 15 weeks prior to screening\n* History of hyperthyroidism not caused by Graves' disease (eg. toxic adenoma, or toxic multinodular goiter) within 6 months before the screening visit\n* Pregnant or lactating women\n* Additional exclusion criteria are defined in the protocol","ALL","18 Years",{"count":19,"type":20},232,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body.\n\nThe study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period. Participants will receive YB-101 or Placebo subcutaneously. Participants who participate in Part 1 can not participate in Part 2.\n\nParticipants will complete 34-39 in-clinic visits in Part 1 or Part 2 over an approximate 40 week period.",[26],"Graves' Disease",[28,26,29,30,31],"Graves'","Hyperthyroidism","Autoimmune thyroid disease","TSH receptor antibodies","RECRUITING","2026-07-27",{"date":35,"type":36},"2026-07-28","ACTUAL",{"date":38,"type":36},"2026-06-10",{"date":40,"type":20},"2029-09",{"name":42,"class":43},"Yarrow Bioscience, Inc.","INDUSTRY",28,""]